GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients

01/21/2022 | 07:01pm EDT

By Josh Beckerman


Gilead Sciences Inc.'s remdesivir, commonly used to treat hospitalized Covid-19 patients, has received Food and Drug Administration approval for some non-hospitalized patients.

Gilead said the expanded indication allows the drug to be administered in qualified outpatient settings that can provide daily intravenous infusions over three consecutive days.

The FDA also expanded the pediatric emergency use authorization to include non-hospitalized pediatric patients younger than 12 who are at high risk of disease progression.

Gilead said "while we continue to advance remdesivir to benefit more patients in multiple settings, we are also advancing our investigational oral compounds. These are based on the same antiviral mechanism of action as remdesivir and a Phase 1 trial for our oral COVID-19 antiviral, GS-5245 is now under way."


Write to Josh Beckerman at josh.beckerman@wsj.com


(END) Dow Jones Newswires

01-21-22 1901ET

All news about GILEAD SCIENCES, INC.
01:00aChina Junshi's potential COVID drug shows promise in small trial
RE
05/17Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Car..
BU
05/17Gilead Sciences, Inc. - FDA Lifts Clinical Hold on Investigational Lenacapavir for the ..
AQ
05/17WALL STREET STOCK EXCHANGE : Finding the tipping point
05/17ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...
05/17Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral ..
MT
05/16Gilead Sciences Says FDA Lifts Hold on Investigational Lenacapavir to Treat HIV
MT
05/16FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention..
BU
05/16U.S. Food and Drug Administration Lifts Clinical Hold on Investigational Lenacapavir fo..
CI
05/16Gilead Sciences Says FDA Lifts Clinical Hold On Injectable Lenacapavir
DJ
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 24 579 M - -
Net income 2022 4 227 M - -
Net Debt 2022 16 479 M - -
P/E ratio 2022 18,4x
Yield 2022 4,60%
Capitalization 79 248 M 79 248 M -
EV / Sales 2022 3,89x
EV / Sales 2023 3,79x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 63,18 $
Average target price 70,07 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-12.99%79 248
REGENERON PHARMACEUTICALS, INC.5.71%71 927
VERTEX PHARMACEUTICALS19.24%66 967
WUXI APPTEC CO., LTD.-16.20%42 682
BIONTECH SE-38.01%38 834
GENMAB A/S-20.15%19 472